Journal article
A pilot randomized controlled trial of the feasibility, acceptability, and impact of giving information on personalized genomic risk of melanoma to the public
AK Smit, D Espinoza, AJ Newson, RL Morton, G Fenton, L Freeman, K Dunlop, PN Butow, MH Law, MG Kimlin, LA Keogh, SJ Dobbinson, J Kirk, PA Kanetsky, GJ Mann, AE Cust
Cancer Epidemiology Biomarkers and Prevention | AMER ASSOC CANCER RESEARCH | Published : 2017
Abstract
Background: Communication of personalized melanoma genomic risk information may improve melanoma prevention behaviors. Methods: We evaluated the feasibility and acceptability of communicating personalized genomic risk of melanoma to the public and its preliminary impact on behaviors and psychosocial outcomes. One hundred eighteen people aged 22 to 69 years provided a saliva sample and were randomized to the control (nonpersonalized educational materials) or intervention (personalized booklet presentingmelanomagenomic risk as absolute andrelative risks and a risk category based on variants in 21 genes, telephonebased genetic counseling, and nonpersonalized educational materials). Intention-to..
View full abstractGrants
Awarded by National Health and Medical Research Council of Australia (NHMRC)
Awarded by Cancer Institute NSW
Awarded by NHMRC Sidney Sax Fellowship
Funding Acknowledgements
This study received funding from Sydney Catalyst Translational Cancer Research Centre and The University of Sydney Cancer Strategic Priority Area for Research Collaboration (SPARC) Implementation Scheme. A.E. Cust received Career Development Fellowships from the National Health and Medical Research Council of Australia (NHMRC; 1063593) and Cancer Institute NSW (15/CDF/1-14). R.L. Morton was supported by a NHMRC Sidney Sax Fellowship (1054216). M.G. Kimlin is supported through a Cancer Council Queensland Professorial Chair in Cancer Prevention.